SciELO - Scientific Electronic Library Online

 
vol.84 número2Evaluación de la expresión de PD-L1 e infiltración linfocitaria intratumoral en carcinoma de mama invasivo triple negativoPercepción de riesgo de infección por HIV y conocimiento sobre uso de antirretrovirales en prevención índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Medicina (Buenos Aires)

versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106

Resumen

ARROSSI, Silvina et al. Effect of COVID-19 pandemics in treatment of cervical cancer: pre/post study. Medicina (B. Aires) [online]. 2024, vol.84, n.2, pp.236-248. ISSN 0025-7680.

Introduction

: Little evidence exists on the impact of the COVID-19 pandemics on the compliance with cervi cal cancer treatment.

Methods

: We carried out a population-based, be fore-and-after retrospective cohort study of all cervical cancer patients diagnosed in the Jujuy province public health sector (n=140), Argentina, between 2017 and 2020. Patients diagnosed in 2020 were considered exposed to the COVID-19 pandemic (n=21). We used multivariable logistic regression to assess the relationship between the pandemics and compliance with treatment. We also measured treatment duration for women who were indicated brachytherapy and time to treatment initia tion by stage.

Results

: Compared with women diagnosed in 2017- 2019 the odds ratio of non-complying with treatment was 1.77 (95%CI 0.59-5.81; p = 0.32) for women diagnosed during 2020. An increased risk of non-compliance was found in patients with prescribed brachytherapy (OR 4.14. 95%CI 1.95-9.11; p < 0.001). Median treatment dura tion for women with prescribed brachytherapy was 12.8 and 15.7 weeks in 2017-2019 vs. 2020 (p = 0.33); median time to treatment initiation for women with early-stage disease was 9 and 5 weeks during 2017-2019 and 2020 respectively (p = 0.06), vs 7.2 and 9 weeks in 2017-2019 and 2020 respectively (p = 0.36) for patients with stages IIB+ disease.

Conclusions

: Low access to brachytherapy was a major determinant of non-compliance. irrespective of the effect of the pandemics.

Palabras clave : Uterine cervical neoplasms; COVID-19; Treatment adherence and compliance; Health services accessibility; Argentina.

        · resumen en Español     · texto en Español     · Español ( pdf )